← Back to Clinical Trials
Recruiting NCT07693621

NCT07693621 Intraperitoneal Dexmedetomidine Versus Magnesium as Adjuvants to Bupivacaine in Laparoscopic Cholecystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07693621
Status Recruiting
Phase
Sponsor Alexandria University
Condition Dexmedetomidine
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2026-05-03
Primary Completion 2026-11-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Bupivacaine 100 mg + dexmedetomidine 1 µg/kgBupivacaine 100 mg + magnesium sulphate 50 mg/kg

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 80 participants in total. It began in 2026-05-03 with a primary completion date of 2026-11-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Although both dexmedetomidine and magnesium sulphate have been individually evaluated as adjuvants to local anesthetics, direct comparisons between the two agents in intraperitoneal instillation during laparoscopic cholecystectomy remain limited. Understanding their relative efficacy and safety could provide valuable guidance for optimizing perioperative analgesia in these patients.

Eligibility Criteria

Inclusion Criteria: * Patients aged 18-60 years * ASA physical status I-II * scheduled for elective laparoscopic cholecystectomy under general anesthesia. Exclusion Criteria: * Known hypersensitivity to study drugs * history of cardiac arrhythmias or conduction abnormalities * severe hepatic/renal impairment * chronic opioid or analgesic use * pregnancy * conversion to open surgery * drain insertion.

Contact & Investigator

Central Contact

sarah m elgamal, MD

✉ sarahelgamal1990@yahoo.com

📞 01005496440

Principal Investigator

sarah m elgamal, MD

PRINCIPAL INVESTIGATOR

Alexandria University

Frequently Asked Questions

Who can join the NCT07693621 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Dexmedetomidine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07693621 currently recruiting?

Yes, NCT07693621 is actively recruiting participants. Contact the research team at sarahelgamal1990@yahoo.com for enrollment information.

Where is the NCT07693621 trial being conducted?

This trial is being conducted at Alexandria, Egypt.

Who is sponsoring the NCT07693621 clinical trial?

NCT07693621 is sponsored by Alexandria University. The principal investigator is sarah m elgamal, MD at Alexandria University. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology